<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729765</url>
  </required_header>
  <id_info>
    <org_study_id>2018035X</org_study_id>
    <nct_id>NCT03729765</nct_id>
  </id_info>
  <brief_title>Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients</brief_title>
  <official_title>A Randomized, Controlled Trial: Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) is a temporary mechanical circulatory support&#xD;
      device for cardiogenic shock (CS) patients. During extracorporeal membrane oxygenation (ECMO)&#xD;
      support, the inflammatory response is intense and complex. It may cause infection, cell&#xD;
      damage, organ dysfunction and even death. Hemoperfusion can adsorb inflammatory factors and&#xD;
      reduce the inflammatory reaction. CS patients who are likely to receive veno-arterial&#xD;
      extracorporeal membrane oxygenation (VA-ECMO) support will be enrolled and randomized with a&#xD;
      1:1 allocation to a simultaneous hemoperfusion arm vs. standard care arm.&#xD;
&#xD;
        1. The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when&#xD;
           extracorporeal membrane oxygenation (ECMO) is commenced.&#xD;
&#xD;
        2. The patients in the standard care arm will not receive hemoperfusion when extracorporeal&#xD;
           membrane oxygenation (ECMO) is commenced.&#xD;
&#xD;
      The primary outcome is the change of plasma interleukin (IL)-6 level after hemoperfusion is&#xD;
      commenced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">July 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of plasma interleukin (IL)-6 level</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>plasma interleukin (IL)-1β、8、10（pg/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>tumor necrosis factor α (TNF-α)（fmol/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>C-reactive protein (CRP)（mg/dl）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Multiple organ dysfunction syndrome (MODS)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>30 days</time_frame>
    <description>Any kinds of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on extracorporeal membrane oxygenation (ECMO) support</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful weaning from extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>30 days</time_frame>
    <description>The circulation doesn't deteriorate in 24 hours since weaning from ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on invasive ventilation</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion</intervention_name>
    <description>The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.</description>
    <arm_group_label>hemoperfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 75 years.&#xD;
&#xD;
          2. Admission to ICU.&#xD;
&#xD;
          3. Criteria for the diagnosis of CS as follows: (1) systolic blood pressure less than 90&#xD;
             mmHg for 30 min, a mean arterial pressure less than 65 mmHg for 30 min, or&#xD;
             vasopressors required to achieve a blood pressure ≥ 90 mmHg; (2) pulmonary congestion&#xD;
             or elevated left-ventricular filling pressures; and (3) signs of impaired organ&#xD;
             perfusion with at least one of the following criteria: (a) altered mental status; (b)&#xD;
             cold, clammy skin; (c) oliguria; and (d) increased serum lactate.&#xD;
&#xD;
          4. ECMO will supply cardiopulmonary support to the patient&#xD;
&#xD;
          5. The patients will be enrolled and randomized when ECMO is commenced less than 24&#xD;
             hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal of consent.&#xD;
&#xD;
          2. Active hemorrhage or thrombocytopenic purpura&#xD;
&#xD;
          3. BMI≥40&#xD;
&#xD;
          4. Received ECMO bridging to a long-term ventricle assist device or heart&#xD;
             transplantation.&#xD;
&#xD;
          5. Infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaotong Hou, PhD., Md.</last_name>
    <phone>86 18911662932</phone>
    <email>xt.hou@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaotong Hou, PhD., MD.</last_name>
      <phone>86 18911662932</phone>
      <email>xt.hou@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaotong Hou, PhD., MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Xiaotong Hou</investigator_full_name>
    <investigator_title>Director of Center for Cardiac Intensive Care</investigator_title>
  </responsible_party>
  <keyword>veno-arterial extracorporeal membrane oxygenation (VA-ECMO)</keyword>
  <keyword>hemoperfusion</keyword>
  <keyword>inflammatory factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

